Burkitt Lymphoma Much Different Than Other B-Cell Lymphomas

Scientists at the National Cancer Institute (NCI) have uncovered the first evidence that Burkitt lymphoma (BL, sometimes called Burkitt's Lymphoma), a highly aggressive B-cell non-Hodgkin's lymphoma, is "fundamentally distinct from other types of lymphoma."

Their research, which has been published online in the journal Nature, uncovered new mutated genes and altered pathways that might give way to therapeutic treatments.

Three clinical subtypes of BL have been recognized:

  • A sporadic subtype affects all ages but is most frequent in children
  • An EBV-associated endemic subtype
  • A human immunodeficiency virus (HIV) associated subtype

In the past, BL was closely linked to the most commonly diagnosed NHL, diffuse large b-cell lymphoma (DLBCL), but recent research has provided the evidence needed to determine distinct differences between the two.

In this study, the NCI researchers concluded that the MYC oncogene was "highly mutated" in BL, and they identified several new mutations in genes that had not before been linked to Burkitt—ones that were almost never found in cases of DLBCL.

In the other direction, they compared BL biopsies to DLBCL biopsies and found mutations in the latter tumors that weren't found in Burkitt.

“Our research suggests a number of targeted therapies that might be less toxic than the high-dose chemotherapy that is typically given to patients with Burkitt lymphoma in the US," said research head Dr. Louis Staudt, "even though they have cure rates approaching 90 percent."

Source: NCI

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap